Sample Letter of Appeal for Natevba® (vevasumab)

[Physician/Practice Letterhead]

Date

Payer Name
Payer Representative
Payer Address
City, State ZIP Code
Payer Fax Number

RE: Coverage of Natevba® (vevasumab)
Patient Name.
Patient DOB
Policy Number
Group Number
Treatment Date and Claim Number
Amount of Claim

Attention: Payer Representative, Claims Department

Dear Director of Claims,

I am writing this letter to request a review of a denied claim for my patient, Patient Name.
On Date of denial , your organization denied this claim for the following reason(s), which are listed on the attached Explanation of Benefits (EOB):

- [Indicate reason(s) for denial from EOB]

Patient Name was prescribed treatment with Natevba® (vevasumab). Natevba® is indicated for the treatment of X-antigen positive non-hodgkins lymphoma in adults.

Consider describing the patient's history, diagnosis, tried and failed treatments and their outcomes. Physicians should excerise medical judgement and discretion.

Full Prescribing Information for Natevba® can be found at www.natevba.com

Treatment with Natevba® is a necessary therapy for this patient's medical condition, and it is my clinical opinion and assessment that Patient Name will benefit from Aimovig®. I trust that the enclosed information, along with my medical recommendations, will establish the medical necessity for payment of this claim.
Please contact me at Office Phone Number if I can provide you with any additional information to approve my request.

Sincerely,

Your Signature

Enclosures:
List enclosures as appropriate: Examples of enclosures include excerpt(s) from patient's medical record, Explanation of Benefits (EOB), relevant treatment guidelines, and product Prescribing Information.

Please see Indication and Important Safety Information on next page.

This page is for your reference only. Content on this page does not need to be sent to the insurance company.

INDICATION

Natevba® (vevasumab) is an antibody-drug conjugate indicated for the first- line treatment of adult patients with X-antigen-positive (XA+) Non-Hodgkin's Lymphoma (NHL)

IMPORTANT SAFETY INFORMATION

Natevba® (vevasumab) is not for everyone, including anyone who has previously had an allergic reaction to Natevba®. It is not for those with hypersensitivity nor patients that currently have or are taking medication for pimozide liver problems or women who are nursing, pregnant, or may become pregnant.

Before starting Natevba®, it is important to evaluate patients thoroughly and prepare for the management of potential adverse events. During treatment, monitor patients closely for any signs or symptoms of severe reactions to ensure appropriate intervention. The following precautions highlight critical areas of concern:

- Infusion-Related Reactions: Severe reactions, including urticaria, hypotension, angioedema, and anaphylaxis, can occur. Premedicate with antihistamines and acetaminophen. For serious reactions, discontinue and manage symptoms.

- Severe Mucocutaneous Reactions: Includes Stevens-Johnson syndrome and toxic epidermal necrolysis, which may be fatal. Discontinue Natevba® if such reactions occur. • Hepatitis B Reactivation: Reactivation can lead to serious outcomes, including death. Screen all patients and consult with experts for managing HBV.

- Progressive Multifocal Leukoencephalopathy (PML): Monitor for new or worsening neurologic symptoms.

- Tumor Lysis Syndrome (TLS): Can occur within 12-24 hours of infusion, potentially leading to renal failure or cardiac issues. Administer prophylaxis and monitor renal function.

- Infections: Serious infections, including bacterial, fungal, and viral, may occur. Monitor closely and treat appropriately.

- Cardiovascular Reactions: Discontinue Natevba® for serious cardiac events, including myocardial infarction and arrhythmias.

ADVERSE REACTIONS

The most common adverse reactions (≥25%) in patients with XA+ Non-Hodgkin's Lymphoma include: Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia, diarrhea, upset stomach, and muscle and joint pain.

DRUG INTERACTIONS

Before initiating treatment with Natevba®, a patient's complete medical history and current medications should be confirmed to identify potential drug interactions and ensure safe administration. Conduct baseline blood tests to evaluate liver function and cholesterol levels in patients with symptoms of liver abnormalities or hyperlipidemia, and monitor these parameters as clinically indicated during treatment. Concomitant use with cisplatin increases the risk of renal toxicity. Monitor renal function closely.

Please see accompanying Natevba® full Prescribing Information.